Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...

Join us on the Dr Reddys Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

The Nifty Pharma index closed on a note on Wednesday. Shares of Dr. Reddy's Laboratories Ltd.(up 1.43 per cent) ended the day ...

Dr. Reddy's Laboratories Ltd. 500124 shares rallied 1.47% to 1,370.60 Indian rupees Wednesday, on what proved to be an ...

Dr Reddy's Laboratories Limited has announced the sale of its step-down wholly owned subsidiary, Dr Reddy's Laboratories ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

Dr Reddy’s Laboratories Inc., USA, the wholly owned subsidiary of the company, has entered into an agreement for the sale of all the issued and outstanding membership interests in its wholly owned ...

The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain generic medications to skyrocket.

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $15.49 and traded ...